Grace Therapeutics (GRCE) Cash from Operations (2019 - 2026)

Grace Therapeutics has disclosed Cash from Operations across 8 years of filings, most recently posting -$3.2 million for Q2 2026.

• In Q2 2026, Cash from Operations fell 78.85% year-over-year to -$3.2 million; the TTM figure through Jun 2026 stood at -$10.3 million (up 21.51% YoY), while the FY2026 annual figure was -$8.9 million, up 40.49% from the prior year.
• Cash from Operations came in at -$3.2 million for Q2 2026 at Grace Therapeutics, down from -$1.7 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of -$1.7 million in Q1 2026 to a low of -$6.2 million in Q2 2023.
• Average Cash from Operations over 5 years is -$3.2 million, with a median of -$3.2 million recorded in 2022.
• Year-over-year, Cash from Operations slumped 117.49% in 2024 and soared 49.92% in 2025.
• Over 5 years, Cash from Operations stood at -$3.7 million in 2022, then surged by 49.17% to -$1.9 million in 2023, then tumbled by 117.49% to -$4.1 million in 2024, then jumped by 45.81% to -$2.2 million in 2025, then plunged by 44.44% to -$3.2 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were -$3.2 million in Q2 2026, -$1.7 million in Q1 2026, and -$2.2 million in Q4 2025.